Analysis of adverse events following the treatment of autologous cytokine-induced killer cells for adoptive immunotherapy in malignant tumour sufferers
Analysis of adverse events following the treatment of autologous cytokine-induced killer cells for adoptive immunotherapy in malignant tumour sufferers
复制标题
DOI：
10.1517/14712598.2015.988134
复制
发表时间：
2015-03
影响因子：
4.6
通讯作者：
Yajing Zhang;L. Xia;Yan Zhang;Yao Wang;Xuechun Lu;F. Shi;Yang Liu;Meixia Chen;K. Feng;Wen-ying Zhang;Xiaobin Fu;W. Han
中科院分区：
文献类型：
--
作者：
Yajing Zhang;L. Xia;Yan Zhang;Yao Wang;Xuechun Lu;F. Shi;Yang Liu;Meixia Chen;K. Feng;Wen-ying Zhang;Xiaobin Fu;W. Han
背景：过继免疫细胞转移，如细胞因子诱导的杀伤细胞(CIK)，已成为肿瘤患者的重要辅助手段。目的：本研究的目的是分析自体CIK细胞输注过程中发生的不良事件，并确定与这些不良事件相关的危险因素。方法：根据美国国家癌症研究所通用术语标准对细胞输注相关不良反应进行评估。分析来自2008年3月至2013年10月期间893名恶性肿瘤患者的单中心数据，这些患者总共接受了4088次输血。结果：893例AEs(1~4级)共215例(5.26%)，其中1~2级204例(94.88%)，24 h内发生156例(72.56%)，最常见的AEs依次为发热(0.88%)、寒战(0.56%)和乏力(0.49%)。少见但严重的不良反应包括过敏性紫癜、肿瘤溶解综合征、过敏性休克、关节痛。没有发现与输血相关的死亡。AEs的相关危险因素主要包括转院周期和临床分期。结论：据我们所知，这是一项关于免疫细胞输注的大样本AEs研究，通过单中心数据分析，揭示了自体CIK细胞治疗对于恶性肿瘤患者来说是一种相当安全和耐受性良好的治疗方式，甚至在少数患者中观察到罕见的严重但不致命的AEs。
Background: Adoptive immune cell transfer such as cytokine-induced killer (CIK) cells has become an important adjuvant approach in patients with tumours. Objectives: The aim of this study was to analyse the adverse events (AEs) that occur during the transfusion of autologous CIK cells and to identify the risk factors associated with these AEs. Methods: Cell infusion-associated AEs were evaluated according to National Cancer Institute Common Terminology Criteria. Analysis was performed from a single-centre data on 893 malignant tumour patients who received a total of 4088 transfusions from March 2008 to October 2013. Results: A total of 215/4088 (5.26%) transfusion cases from 893 patients presented with AEs (Grade 1 – 4); 204/215 (94.88%) were Grade 1 – 2, and 156/215 (72.56%) occurred within 24 h. The most common AEs were fever (0.88%), chills (0.56%) and fatigue (0.49%). The rare but severe AEs included anaphylactoid purpura, tumour lysis syndrome, anaphylactic shock, arthralgia. No transfusion-associated death was noticed. The mainly relative risk factors for AEs included transfer cycles and clinical stages. Conclusion: This study is a large-sample AEs research, to our knowledge, relative to immune cell transfusion from a single centre data analysis, revealing that autologous CIK cell therapy represents a fairly safe and well-tolerated treatment modality for malignant tumour patients, even rare severe, but not lethal AEs were observed in few patients.